WALTHAM, MA -- February 15, 2007 -- PerkinElmer, Inc. (NYSE: PKI), a global leader in Health Sciences and Drug Discovery, recently showcased its expertise and technologies in advanced cellular imaging, screening and analysis at the 2007 LabAutomation Conference, January 27-31, Palm Beach, Calif. PerkinElmer hosted three informative, user-focused workshops, and demonstrated its high-performance modular liquid handling workstations and powerful screening platforms, including several new and recently acquired products in cutting-edge GPCR and High Content Screening (HCS) technologies.
“New laboratory technologies continue to advance the important work of biomolecular research and drug discovery,” said Kenneth King, vice president and general manager, Molecular Medicine Business Element for PerkinElmer’s Life and Analytical Sciences business. “With our expanding portfolio of technologies and deep scientific expertise, particularly in the area of cellular sciences, PerkinElmer is able to deliver the comprehensive, high-performance solutions which are essential to automating and managing experimental workflows in demanding, modern laboratory environments.”
New to LabAutomation 2007
EnVision™ TRF Laser — This compact nitrogen laser module for the flexible EnVision Multilabel Plate Reader provides considerably improved performance for homogeneous time-resolved fluorescence (TRF) assays when compared to flash light excitation detection systems.
AlphaLISA™ technology — A highly sensitive, homogenous alternative to ELISA, this exclusive assay platform offers a wide dynamic range and easy automation.
Euroscreen Products and Evotec Technologies — PerkinElmer highlighted Euroscreen Products' advanced GPCR technology and Evotec Technologies' highly regarded HCS systems, including Opera, which were added to PerkinElmer’s product portfolio following their recent acquisition.
Technology Showcase
Additional technologies that PerkinElmer exhibited throughout the LabAutomation conference include:
JANUS Automated Workstation — PerkinElmer’s breakthrough modular liquid handling solution with proprietary Modular Dispense technology (MDT) provides real-time and future adaptability in throughput, capacity and complete walk-away application capabilities.
JANUS Cellular Workstation — A fully automated liquid handling platform designed for cellular assays, the JANUS Cellular Workstation integrates cutting-edge PerkinElmer technologies including automation, detection, and chemistries into complete application solutions for drug discovery and research.
FlexDrop™ PLUS Precision Reagent Dispenser — The newest version of the popular FlexDrop dispensing system has been enhanced for easier use and minimizes reagent consumption. FlexDrop PLUS delivers superior dispense precision at nanoliter volumes.
LumiLux Cellular Screening Platform — Breakthrough walk-away uHTS cellular imaging platform for both kinetic flash and glow luminescence assays using either adherent or suspension cells.
ViewLux™ ultraHTS Microplate Imager — This multilabel imager provides high sensitivity, extremely fast microplate imaging, and delivers throughput in excess of 200,000 samples per hour using 1536-well plates.
LANCEUltra technology — A new, improved homogenous TRF platform for TR-FRET assays enabling higher sensitivity, speed, and productivity in PerkinElmer’s high-throughput screening assay platform.
AlphaScreen SureFire assays — Enables researchers to easily screen GPCR activation in whole cells, through homogenous non-radioactive measurement of phosphor-ERK ½ in whole cell lysates.
Interactive, User-Focused Workshops
Automated Approaches to Biomarker Discovery, High Throughput RNAi Screening, and Cellular GPCR and Kinase Assays — This workshop examined several new automated approaches to biomarker discovery featuring the JANUS™ Automated Workstation for sample preparation and discussed a new ELISA replacement technology, AlphaLISA™, for biomarker detection. Recent advances in the automation of genetic analyses were also presented. Also, various approaches to cellular GPCR and Kinase screening featuring the LANCE® cAMP, SureFire™ Cellular Kinase platform and the LumiLux™ Cellular Screening Platform were presented.
New Validation and Optimization Techniques for the PerkinElmer JANUS platform Using the Artel MVS Multichannel Verification System — Users of automated liquid handlers need to ensure the accuracy and precision performance of their equipment in order to satisfy their quality system and regulatory requirements. Workshop participants learned about the latest capabilities of Artel MVS technology as well as the performance capabilities of the PerkinElmer JANUS Automated Workstation.
Automated Screening Solutions from PerkinElmer — PerkinElmer presented innovative solutions in automated liquid handling, detection and reagents for cellular screening. The JANUS portfolio of scaleable and modular automation systems will be presented demonstrating flexible high throughput solutions. Data for LANCE cAMP and luminescence cellular assays generated on the new JANUS Cellular Workstation was featured. Enabling assay miniaturization technologies were discussed featuring the NanoHead™. The LumiLux Cellular Screening Platform coupled with the flash luminescence aequorin technology and the new AlphaScreen® SureFire assay for cellular measurement of phosphorylated ERK1/2 kinases were also presented.
Factors Affecting Future Performance
This press release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as “believes,” “intends,” “anticipates,” “plans,” “expects,” “projects,” “forecasts,” “will” and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management’s current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) our failure to introduce new products in a timely manner; (2) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable; (3) our failure to protect adequately our intellectual property; (4) the loss of any of our licenses or licensed rights; (5) our ability to compete effectively; (6) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (7) our ability to produce an adequate quantity of products to meet our customers’ demands; (8) our failure to maintain compliance with applicable government regulations; (9) regulatory changes; (10) economic, political and other risks associated with foreign operations; (11) our ability to retain key personnel; (12) restrictions in our credit agreement; (13) our ability to realize the full value of our intangible assets; and (14) other factors which we describe under the caption “Risk Factors” in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.
Other Information
Health Sciences end markets include genetic screening, environmental, service, biopharma, and medical imaging. Photonics markets include sensors and specialty lighting.